Use of IGHV3–21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post–germinal center leukemogenic selection
Emanuela M. Ghia(University of California San Diego), Thomas J. Kipps(University of California San Diego), Laura Z. Rassenti(University of California San Diego), Jennifer R. Brown(Dana-Farber Cancer Institute), Michael J. Keating(The University of Texas MD Anderson Cancer Center), George F. Widhopf(University of California San Diego), Sonia Jain(University of Antwerp), John G. Gribben(Queen Mary University of London), William G. Wierda(The University of Texas MD Anderson Cancer Center), John C. Byrd(University of Cincinnati), Andrew Greaves(University of California San Diego), Neil E. Kay(Mayo Clinic)
Cited by 71
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k